We’re proud to share a major milestone for the A-TANGO Consortium: the latest publication is now available in the Journal of Hepatology:
Highlights of this important publication:
- This study in global cohorts of patients with acute decompensation of cirrhosis aimed to develop a new organ failure (OF) scoring system to make it more suitable for accurate detection of acute-on-chronic liver failure (ACLF) for clinical trials.
- This A-TANGO organ failure score was developed in a cohort of 3896 patients from Europe and Latin America and shown to improve the diagnostic accuracy and performance compared with the most widely and currently applied score (CLIF-C OF score).
- The A-TANGO organ failure score was validated in two large cohorts from India and China.
- The A-TANGO OF score is an enhanced version of the CLIF-C OF score, which improved the diagnosis of ACLF and can be used for patient inclusion and endpoints for clinical trials of ACLF.
Background:
Acute-on-chronic liver failure (hashtag#ACLF) remains one of the most devastating complications of advanced liver disease, with high short-term mortality and limited therapeutic options. Many patients still rely on liver transplantation as the only life-saving treatment.
The -TANGO Consortium is working to change that!
The collaborative and international A-TANGO project brings together clinicians, researchers, patient organisations, and industry partners across Europe to develop a novel combinatorial therapy (G-TAK) targeting two key drivers of ACLF:
- Inflammation, through inhibition of Toll-like receptor-4 (hashtag#TRL4)
- Impaired liver regeneration, through mobilisation of stem cells with G-CSF (granulocyte colony-stimulating factor)
Together, this strategy aims to both reduce inflammation and stimulate liver repair, offering a new therapeutic avenue for patients with ACLF.